Jonathan Tobin

Jonathan Tobin is currently a Partner at Brandon Capital, focused on leading investments in biotech companies globally. Jonathan has also held roles as a Non Executive Director at CatalYm GmbH, NRG Therapeutics, and Pheon Therapeutics, as well as a Board Observer at Myricx Pharma Ltd and a Member of the Investment Advisory Committee at KHAN Technology Transfer Fund I. In 2021, they also became a Commercial Partnerships Advisor at Genomics England. Previously, they were a Managing Director at Arix Bioscience plc from 2016-2020, during which time they were involved in investments in Artios Pharma, VelosBio (acquired by Merck), Depixus, STipe Therapeutics, Atox Bio, Quench Bio, Pyxis Oncology, TwelveBio, and Gensight (Euronext). Additionally, they were a Non Executive Director at Depixus in 2020, and a Non Executive Director at Stipe Therapeutics from 2019-2020, where they co-led the €20m Series A to get the lead compound through pre-clinical development.

Jonathan Tobin attended Haberdashers' Aske's School from 1994 to 2001. Jonathan then went on to pursue a MA in Biological Science at the University of Oxford from 2002 to 2005. Following this, they completed a PhD in Molecular Medicine at UCL from 2005 to 2008. Finally, they obtained an MBA in Business Administration and Management, General from Imperial College London from 2010 to 2013.